Ionis Pharmaceuticals Inc. (IONS) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Ionis Pharmaceuticals’s revenue went from $373M in fiscal 2016 to $944M in fiscal 2025, growth of about 10.9% a year.
Net income in fiscal 2025 was -$381M, a net margin of -40.4%; the best year in this period was 2019 with $278M.
Over the twelve months to September 30, 2026, revenue was $960M and net income -$547M.
Free cash flow was -$320M in fiscal 2025 and positive in 5 of the 10 years shown.
The diluted share count rose 32% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $960M | $944M | $705M | $788M | $587M | $810M | $729M | $1.1B | $600M | $508M | $373M |
| Gross profit | $943M | $928M | $694M | $779M | $573M | $800M | $717M | $1.1B | $598M | $508M | $373M |
| Operating income | -$565M | -$382M | -$475M | -$354M | -$410M | -$30M | -$172M | $366M | -$61M | $31M | -$20M |
| Net income | -$547M | -$381M | -$454M | -$366M | -$270M | -$29M | -$444M | $278M | $274M | $346000 | -$60M |
| EPS (diluted) | $-3.32 | $-2.38 | $-3.04 | $-2.56 | $-1.90 | $-0.20 | $-3.18 | $1.90 | $2.07 | $0.15 | $-0.50 |
| R&D | — | $916M | $902M | $900M | — | $638M | $531M | $462M | $412M | $372M | $340M |
| Revenue growth | — | +33.8% | −10.5% | +34.1% | −27.5% | +11.1% | −35.0% | +87.2% | +18.1% | +36.2% | +31.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$544M | -$269M | -$501M | -$308M | -$274M | $31M | $36M | $346M | $603M | $174M | -$112M |
| Capital spending | -$72M | -$51M | -$45M | -$24M | -$16M | -$12M | -$35M | -$31M | -$14M | -$35M | -$7M |
| Free cash flow | -$616M | -$320M | -$546M | -$331M | -$290M | $19M | $772000 | $315M | $589M | $139M | -$119M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | — | — | $0 | $0 | $91M | $34M | $0 | $0 | — |
| Stock-based pay | $176M | $134M | $130M | $106M | $100M | $121M | $230M | $147M | $131M | $86M | $72M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $2.7B | $2.3B | $2.3B | $2.0B | $2.1B | $1.9B | $2.5B | $2.1B | $1.0B | $665M |
| Debt | — | $2.1B | $1.4B | $1.5B | $1.4B | $22M | $857M | $805M | $582M | $535M | $502M |
| Equity | — | $489M | $588M | $387M | $573M | $772M | $743M | $1.5B | $1.0B | $281M | $100M |
| Total assets | — | $3.5B | $3.0B | $3.0B | $2.5B | $2.6B | $2.4B | $3.2B | $2.7B | $1.3B | $912M |
| Shares (diluted) | 166M | 160M | 150M | 143M | 142M | 141M | 140M | 153M | 134M | 126M | 121M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 98.2% | 98.3% | 98.4% | 98.8% | 97.6% | 98.7% | 98.4% | 99.6% | 99.7% | 100.0% | 100.0% |
| Operating margin | -58.8% | -40.5% | -67.4% | -44.9% | -69.8% | -3.7% | -23.6% | 32.6% | -10.2% | 6.1% | -5.4% |
| Net margin | -56.9% | -40.4% | -64.4% | -46.5% | -45.9% | -3.5% | -60.9% | 24.8% | 45.6% | 0.1% | -16.2% |
| FCF margin | -64.2% | -33.9% | -77.5% | -42.1% | -49.4% | 2.3% | 0.1% | 28.0% | 98.3% | 27.5% | -32.0% |
| ROIC | — | -11.7% | -23.3% | -14.9% | -16.6% | -3.7% | -8.5% | 13.6% | -3.0% | 2.5% | -2.6% |
| ROE | — | -78.0% | -77.1% | -94.7% | -47.1% | -3.7% | -59.8% | 18.9% | 26.1% | 0.1% | -60.7% |
Frequently asked questions
What is Ionis Pharmaceuticals’s annual revenue?
$944M in fiscal 2025 and $960M over the twelve months to September 30, 2026.
How much profit does Ionis Pharmaceuticals make?
Net income was -$381M in fiscal 2025 (net margin -40.4%).
Is Ionis Pharmaceuticals’s revenue growing?
Yes: revenue rose 33.8% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.